According to Halozyme Therapeutics's latest financial reports the company's total debt is $1.50 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2022-12-31 | $1.50 B | 71.8% |
2021-12-31 | $0.87 B | 120.7% |
2020-12-31 | $0.39 B | -1.33% |
2019-12-31 | $0.40 B | 218.55% |
2018-12-31 | $0.12 B | -37.54% |
2017-12-31 | $0.20 B | -6.59% |
2016-12-31 | $0.21 B | 334.69% |
2015-12-31 | $49.83 M | -0.05% |
2014-12-31 | $49.86 M | 0.18% |
2013-12-31 | $49.77 M | 59.98% |
2012-12-31 | $31.11 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $39.65 B | 2,533.22% | ๐บ๐ธ USA |
![]() Pfizer PFE | $34.87 B | 2,215.25% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $18.88 B | 1,153.81% | ๐บ๐ธ USA |
![]() Sanofi SNY | $22.71 B | 1,408.37% | ๐ซ๐ท France |
![]() Baxter BAX | $16.88 B | 1,021.37% | ๐บ๐ธ USA |
![]() MannKind Corp MNKD | $0.38 B | -74.58% | ๐บ๐ธ USA |